{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:26:28Z","timestamp":1773930388589,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/200.330\/2024"],"award-info":[{"award-number":["E-26\/200.330\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/200.331\/2024"],"award-info":[{"award-number":["E-26\/200.331\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["305077\/2021\\u20130"],"award-info":[{"award-number":["305077\/2021\\u20130"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["305544\/2022\\u20135"],"award-info":[{"award-number":["305544\/2022\\u20135"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["406928\/2023\\u20131"],"award-info":[{"award-number":["406928\/2023\\u20131"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105071","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:27:34Z","timestamp":1764980854000},"page":"105071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aromatase inhibitors and medication-related osteonecrosis of the jaw: Friends, foes, or bystanders?"],"prefix":"10.1016","volume":"218","author":[{"given":"Soraia","family":"Macari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f4ice Dias","family":"Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Zanetti","family":"Drumond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breno Amaral","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Alves da Silva","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Guimar\u00e3es","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois C\u00f4me","family":"Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.J.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Alcides Almeida","family":"de Arruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-7835","authenticated-orcid":false,"given":"Tarc\u00edlia Aparecida","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2025.105071_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12094-006-0157-y","article-title":"Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern","volume":"8","author":"Aguiar Bujanda","year":"2006","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the food and drug administration adverse event reporting System (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105071_bib3","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1530\/ERC-21-0293","article-title":"Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer","volume":"29","author":"Alataki","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105071_bib4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/jpm14040371","article-title":"Preventing bone loss in breast cancer patients: designing a personalized clinical pathway in a large-volume research hospital","volume":"14","author":"Amar","year":"2024","journal-title":"J. Pers. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijom.2015.09.025","article-title":"Mitoxantrone as a contributing factor in medication-related osteonecrosis of the jaws","volume":"45","author":"Bagan","year":"2016","journal-title":"Int. J. Oral. Maxillofac. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J. Oral. Pathol. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105071_bib7","article-title":"Identified medications causing medication-related osteonecrosis of the jaw: a literature review","volume":"17","author":"Baghalipour","year":"2025","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11845-019-02120-6","article-title":"Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit","volume":"189","author":"Bal","year":"2020","journal-title":"Ir. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.11124\/JBIES-24-00103","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies","volume":"23","author":"Barker","year":"2025","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.critrevonc.2025.105071_bib10","doi-asserted-by":"crossref","DOI":"10.11124\/JBIES-24-00103","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for analytical cross-sectional studies","author":"Barker","year":"2025","journal-title":"JBI Evid. Synth."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105071_bib12","doi-asserted-by":"crossref","first-page":"18317","DOI":"10.1002\/cam4.6429","article-title":"A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab","volume":"12","author":"Bracchi","year":"2023","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105071_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105071_bib14","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.3390\/ijms22126559","article-title":"Is the jaw bone micro-structure altered in response to osteoporosis and bisphosphonate treatment? A micro-CT analysis","volume":"22","author":"Chatterjee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105071_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.oooo.2024.05.014","article-title":"Medication-related osteonecrosis of the jaw (MRONJ) systemic review: mevalonate pathway mechanisms explored","volume":"138","author":"Cho","year":"2024","journal-title":"Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105071_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105071_bib19","first-page":"7195","article-title":"The possible different roles of denosumab in prevention and cure breast cancer bone metastases: a 'hypothesis-generator' study from clinical practice","volume":"16","author":"Cortellini","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.105071_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.829875","article-title":"Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of randomized controlled trials","volume":"11","author":"de Sire","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224455","article-title":"Medication-related osteonecrosis (MRONJ) of the mandible and maxilla","volume":"13","author":"Dunphy","year":"2020","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.critrevonc.2025.105071_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/421746","article-title":"Biology of bone tissue: structure, function, and factors that influence bone cells","volume":"2015","author":"Florencio-Silva","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"4A","key":"10.1016\/j.critrevonc.2025.105071_bib23","first-page":"1841","article-title":"Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients","volume":"27","author":"Friedrich","year":"2007","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105071_bib24","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.21873\/anticanres.15324","article-title":"Consolidation of tumorous mandibular ramus defect during denosumab treatment for rapidly progressive metastatic breast cancer","volume":"41","author":"Friedrich","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2025.105071_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.critrevonc.2025.105071_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1249160","article-title":"Aromatase inhibitors: the journey from the state of the art to clinical open questions","volume":"13","author":"Generali","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104085","article-title":"Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients","volume":"10","author":"Gravina","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.105071_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100694","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG","volume":"53","author":"Hadji","year":"2025","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.critrevonc.2025.105071_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138237","article-title":"The role of Google Scholar in evidence reviews and its applicability to grey literature searching","volume":"10","author":"Haddaway","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105071_bib33","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.joms.2007.03.021","article-title":"Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Herbozo","year":"2007","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105071_bib34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcms.2017.01.013","article-title":"Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ)","volume":"45","author":"Hoefert","year":"2017","journal-title":"J. Craniomaxillofac Surg."},{"key":"10.1016\/j.critrevonc.2025.105071_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713700","article-title":"Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management","volume":"12","author":"Hyder","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1634\/theoncologist.2007-0159","article-title":"Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study","volume":"13","author":"Ibrahim","year":"2008","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib37","first-page":"648","article-title":"Breast cancer patients receiving denosumab during adjuvant aromatase inhibitors treatment: who are the \"inadequate responders\" patients to denosumab?","volume":"25","author":"Irelli","year":"2020","journal-title":"J. BUON"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Min. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J. Clin. Densitom."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.afos.2022.05.003","article-title":"The impact of sex steroids on osteonecrosis of the jaw","volume":"8","author":"Kim","year":"2022","journal-title":"Osteoporos. Sarcopenia"},{"key":"10.1016\/j.critrevonc.2025.105071_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdcr.2021.12.007","article-title":"Skin involvement of medication-related osteonecrosis of jaws in an immunocompromised, bisphosphonate-treated patient","volume":"20","author":"Kim","year":"2021","journal-title":"JAAD Case Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105071_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/dj11050109","article-title":"Medication-related osteonecrosis: why the jawbone?","volume":"11","author":"Kuehn","year":"2023","journal-title":"Dent. J. (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105071_bib43","article-title":"Denosumab-associated osteonecrosis of the jaw; a case series and literature review","volume":"9","author":"Kyriakidou","year":"2016","journal-title":"Br. J. Med. Pract."},{"key":"10.1016\/j.critrevonc.2025.105071_bib44","doi-asserted-by":"crossref","first-page":"033","DOI":"10.23937\/2469-5734\/1510033","article-title":"Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report","volume":"2","author":"Lee","year":"2016","journal-title":"Int. J. Oral. Dent. Health"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105071_bib45","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib46","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral. Patol. Oral. Cir. Bucal"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105071_bib47","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.3390\/jcm10204762","article-title":"Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset","volume":"10","author":"Marcian\u00f2","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105071_bib48","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12903-023-02732-6","article-title":"MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series","volume":"23","author":"Mauceri","year":"2023","journal-title":"BMC Oral. Health"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-020-05640-3","article-title":"Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis","volume":"181","author":"Miyashita","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.105071_bib51","doi-asserted-by":"crossref","unstructured":"Moola S., Munn Z., Tufanaru C., Aromataris E., Sears K., Sfetcu R., et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E., Munn Z., editors. JBI manual for evidence synthesis. Adelaide: JBI; 2020 [cited 2025 Sep 16]. Available from: \u3008https:\/\/synthesismanual.jbi.global\u3009.","DOI":"10.46658\/JBIRM-17-06"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105071_bib52","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.critrevonc.2025.105071_bib54","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2147\/TCRM.S167579","article-title":"Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study","volume":"14","author":"Nakatsukasa","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105071_bib55","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.3390\/cancers17172726","article-title":"Aromatase inhibitors as adjuvant therapy in early breast cancer: insights into toxicities and their management","volume":"17","author":"Nardin","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib56","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","article-title":"Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals","volume":"42","author":"Neha","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Nicolatou-Galitis","year":"2019","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio."},{"key":"10.1016\/j.critrevonc.2025.105071_bib58","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res. Notes"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105071_bib59","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/annonc\/mdr600","article-title":"Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study","volume":"23","author":"Nuzzo","year":"2012","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00774-020-01138-6","article-title":"The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results","volume":"39","author":"Ouchi","year":"2021","journal-title":"J. Bone Min. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105071_bib62","article-title":"Medication-related osteonecrosis of the jaw induced by a CDK 4\/6 inhibitor (palbociclib) in a patient who was na\u00efve to antiresorptive bone therapy: a case report","volume":"4403","author":"Pallois","year":"2025","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MBC.0000000000000047","article-title":"Testosterone, anastrozole, factor V Leiden heterozygosity and osteonecrosis of the jaws","volume":"25","author":"Pandit","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.critrevonc.2025.105071_bib64","article-title":"Three-dimensional bone evaluation after surgical treatment with plasma rich in growth factors of medication related osteonecrosis of the jaw (MRONJ): a report of 3 cases","volume":"10","author":"Pardi\u00f1as L\u00f3pez","year":"2019","journal-title":"Bone Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105071_bib65","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.bjoms.2024.08.008","article-title":"Management of medication-related osteonecrosis of the jaw: an overview of national and international guidelines","volume":"62","author":"Patel","year":"2024","journal-title":"Br. J. Oral. Maxillofac. Surg."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105071_bib66","article-title":"Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?","volume":"94","author":"Pilanci","year":"2015","journal-title":"Med. (Baltim.)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib67","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1530\/JOE-16-0666","article-title":"Mechanical, hormonal and metabolic influences on blood vessels, blood flow and bone","volume":"235","author":"Prisby","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.105071_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.700397","article-title":"18F-fluoride PET\/CT imaging of medication-related osteonecrosis of the jaw in conservative treatment-a case report","volume":"11","author":"Reinert","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105071_bib69","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"5-6","key":"10.1016\/j.critrevonc.2025.105071_bib70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000334456","article-title":"The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial","volume":"81","author":"Safra","year":"2011","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105071_bib71","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/annonc\/mdl163","article-title":"Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer","volume":"17","author":"Sanna","year":"2006","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1548-5315(11)70023-7","article-title":"Osteonecrosis of the jaw associated with bisphosphonate therapy: tips for the practicing oncologist","volume":"4","author":"Sehbai","year":"2007","journal-title":"Community Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib73","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/curroncol31010016","article-title":"Relationship between medication-related osteonecrosis of the jaw and CDK4\/6 inhibitors in breast cancer","volume":"31","author":"Sen\u00edn","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105071_bib74","doi-asserted-by":"crossref","DOI":"10.1590\/1807-3107bor-2025.vol39.023","article-title":"Bone mineral density in patients using aromatase inhibitors: a clinical, nutritional, and quality of life assessment","volume":"39","author":"Souza","year":"2025","journal-title":"Braz. Oral. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105071_bib75","doi-asserted-by":"crossref","first-page":"196","DOI":"10.36401\/JIPO-21-14","article-title":"Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis","volume":"4","author":"Srivastava","year":"2021","journal-title":"J. Immunother. Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.105071_bib76","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.2147\/OTT.S115058","article-title":"Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole","volume":"9","author":"Sun","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2025.105071_bib77","first-page":"535","article-title":"Osteonecrosis of the jaw in a patient taking once-yearly infusion of zoledronic acid for osteopenia","volume":"2","author":"Tanaka","year":"2013","journal-title":"Case Rep. Clin. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64440-7","article-title":"Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management","volume":"14","author":"Tani","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00223-025-01362-0","article-title":"Bone effects of anti-cancer treatments in 2024","volume":"116","author":"Teissonni\u00e8re","year":"2025","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105071_bib80","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/bcp.14681","article-title":"Medication-related osteonecrosis of the jaw: analysing the range of implicated drugs from the Australian database of adverse event notifications","volume":"87","author":"Teoh","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105071_bib81","first-page":"467","article-title":"Comprehensive study of the risk factors for medication-related osteonecrosis of the jaw based on the Japanese adverse drug event report database","volume":"13","author":"Toriumi","year":"2020","journal-title":"Pharm. (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105071_bib82","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/JCO.2009.21.8784","article-title":"Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer","volume":"28","author":"Traina","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105071_bib83","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern Medl"},{"key":"10.1016\/j.critrevonc.2025.105071_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2011.5244","article-title":"Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates","volume":"2012","author":"U\u00f1a","year":"2012","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105071_bib85","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1159\/000541391","article-title":"Surviving twenty years to bone and liver metastatic breast cancer: a case reported by treating oncologists and the patient herself","volume":"17","author":"Valerio","year":"2024","journal-title":"Case Rep. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105071_bib86","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.21.00311","article-title":"Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer (BOOG 2006-04): randomized phase III TEAM-IIB trial","volume":"40","author":"Vliek","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105071_bib87","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib88","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2016.1100","article-title":"Osteonecrosis of the jaw associated with everolimus: a case report","volume":"6","author":"Yamamoto","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105071_bib89","first-page":"547","article-title":"MASCC\/ISOO clinical practice statement: adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw","volume":"32","author":"Yarom","year":"2024","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105071_bib90","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1556331621995846","article-title":"Vertebral fractures after denosumab discontinuation in breast cancer survivors: a single institution experience","volume":"17","author":"Yeung","year":"2021","journal-title":"HSS J."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105071_bib91","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1177\/10781552231165434","article-title":"Osteonecrosis of the jaw under palbociclib: a case series description","volume":"29","author":"Yosofi","year":"2023","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105071_bib92","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/biomedicines12081708","article-title":"Adverse event profiles of the third-generation aromatase inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2025.105071_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103114","article-title":"Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: a systemtic review and meta-analysis","volume":"156","author":"Zhao","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105071_bib94","article-title":"Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration Adverse Event Reporting System","volume":"9","author":"Zhong","year":"2025","journal-title":"JBMR"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:31:11Z","timestamp":1773919871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":94,"alternative-id":["S1040842825004597"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105071","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aromatase inhibitors and medication-related osteonecrosis of the jaw: Friends, foes, or bystanders?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105071"}}